Cerebral Lymphoma B Cell Refractory Clinical Trial
Official title:
Phase II Study Evaluating the Combination Pegylated Liposomal Doxorubicin and Dexamethasone for the Treatment of Immunocompetent Patients With Cerebral Lymphoma Relapsed or Refractory to First-line Chemotherapy Containing High Dose Methotrexate (MTXHD) and / or High-dose Cytarabine.
The protocol is to assess the overall response rate (complete response and partial response)
of treatment with non-pegylated liposomal doxorubicin at a dose of 50 mg / m² in combination
with dexamethasone in immunocompetent adult patients with primary brain lymphoma large
B-cell refractory or relapsed after first-line treatment MTXHD and high-dose cytarabine,
excluding strict eye lymphomas.
This is a Phase II, open, prospective, multicenter, non-comparative with direct individual
benefit.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment